SLS
NASDAQ · Biotechnology
Sellas Life Sciences Group I
$4.93
-0.02 (-0.40%)
Financial Highlights (FY 2025)
Revenue
353.66M
Net Income
19.39M
Gross Margin
46.3%
Profit Margin
5.5%
Rev Growth
-7.4%
D/E Ratio
0.38
Revenue & Net Income
Margin Trends
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Gross Margin | 46.3% | 46.3% | 46.3% |
| Operating Margin | 6.7% | 6.0% | 6.6% |
| Profit Margin | 5.5% | 5.9% | 6.7% |
Income Statement
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 353.66M | 369.01M | 305.89M |
| Gross Profit | 163.57M | 170.67M | 141.48M |
| Operating Income | 23.68M | 22.20M | 20.31M |
| Net Income | 19.39M | 21.88M | 20.34M |
| Gross Margin | 46.3% | 46.3% | 46.3% |
| Operating Margin | 6.7% | 6.0% | 6.6% |
| Profit Margin | 5.5% | 5.9% | 6.7% |
| Rev Growth | -7.4% | -1.2% | +17.7% |
Balance Sheet
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Total Debt | 144.09M | 139.48M | 147.73M |
| Total Equity | 382.94M | 344.76M | 361.90M |
| D/E Ratio | 0.38 | 0.40 | 0.41 |
Cash Flow
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| EBITDA | 24.66M | 25.78M | 21.04M |
| Free Cash Flow | 20.13M | 23.20M | 18.29M |